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analysis revealed that if both utilities were tested at the
high or low end of their ranges, they were no longer 
sensitive. CONCLUSIONS: Both drugs, given their low
potential for drug-drug interactions, time-released for-
mulations, and lack of anticholinergic side effects, are
appropriate for use in the elderly and may improve
overall quality of life. However, the results suggest that
bupropion SR may be a more cost-effective choice of anti-
depressant pharmacotherapy in an elderly population,
particularly in patients concerned about potential adverse
sexual side effects.
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UTILIZATION AND COST OF ATYPICAL
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OBJECTIVE: To quantify differences in resource utiliza-
tion and healthcare cost between olanzapine and risperi-
done when used as augmentation agents in patients with
depression. METHODS: We conducted a retrospective
analysis using the California Medicaid database (Medi-
Cal 1996–2000). Adult patients aged 18 to 65 with 1 year
of continuous enrollment and one or more medical claims
for depression were included in the analysis. Patients 
with schizophrenia or psychotic depression were
excluded. Treatment groups consisted of patients who
received augmentation with risperidone or olanzapine
after completing at least four weeks of antidepressant
treatment. Cost comparisons were made using the
amount paid by Medi-Cal to providers over the six-
month period following the initiation of antidepressant
treatment. RESULTS: Risperidone (N = 105) and olan-
zapine (N = 130) groups were similar with respect to
length of treatment, use of antidepressants, and occur-
rence and number of outpatient and inpatient visits.
Mean antipsychotic costs per month were signiﬁcantly
lower for risperidone ($154.31 vs. $258.13, p < 0.0001).
A signiﬁcantly higher proportion of risperidone subjects
(62.9% vs. 39.2% for olanzapine) had total mental
healthcare costs that were below the median (p = 0.0003).
CONCLUSIONS: Relative to olanzapine, augmentation
with risperidone was associated with signiﬁcantly lower
antipsychotic and total mental health costs.
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OBJECTIVES: To compare the costs and effectiveness 
of Methadone Maintenance Treatment (MMT) and
Buprenorphine Maintenance Treatment (BMT) among
stabilized opioid dependent patients. METHODS: A cost
analysis was performed. One hundred forty-ﬁve patients,
on either treatment between 1 month and 12 months,
were selected from 28 randomly chosen community phar-
macies. Questionnaires were issued to 135 community
pharmacies, of which 67 (including these 28) validly
responded for costing these 2 services. (24 of the phar-
macies did not provide either of these services.) A treat-
ment sector perspective was chosen. Costs incurred at the
Commonwealth government, pharmacy and patient levels
were investigated. ANOVA models were applied to test
for differences while controlling for length on program.
Effectiveness was measured as change in opioid-free days.
RESULTS: At the Commonwealth government level,
costs of the medicines and doctor visits were taken into
account. The estimated monthly cost (SD) per methadone
patient was AUD$62.8 ($32.6) and AUD$169.0 ($33.7)
per buprenorphine patient. Costs of medicines comparing
treatments showed a signiﬁcant difference (p = 0.000) but
doctor visits showed none (p = 0.609). At the pharmacy
level, the estimated monthly cost (SD) of one MMT
patient was AUD$104.3 ($24.5) and AUD$128.2 ($40.3)
per BMT patient (p = 0.005). At the patient level, median
monthly fees (range) for dispensing and transportation
were $128.0 ($61.3–$234.7) per MMT patient whereas
$156.0 ($66.0–$394.7) per BMT patient. The difference
lay in the monthly transportation fee (p = 0.008). During
the ﬁrst year of treatment, estimated mean total cost (SD)
on one MMT patient was $306.2 ($51.2) monthly, but
$465.8 ($66.4) for one BMT patient (p = 0.000). The
average change in opioid-free days (SD) out of 30 was
27.7 (5.7) days for MMT, and 26.0 (7.2) days for BMT
patients (p = 0.102). CONCLUSIONS: Signiﬁcant differ-
ences in costs of MMT and BMT were identiﬁed. MMT
was less costly but resulted in the same overall change in
opioid-free days.
PMH46
COST CONSEQUENCES OF APPLYING
APPROPRIATE USE EDITS TO SELECT
HYPNOTIC AGENTS:A RETROSPECTIVE
COMPARATIVE ANALYSIS
Chiefari DM
NMHCrx, Latham, NY, USA
OBJECTIVE: To determine the economic impact of an
appropriate use edit placed on select non-benzodiazepine
hypnotic agents for an HMO client. METHOD: Zolpi-
dem and zaleplon are non-benzodiazepine hypnotics indi-
cated for the short-term treatment of insomnia, generally
7–10 days. Comparator HMO 1, with approximately
380,000 members, instituted an appropriate use edit
allowing for 14 days of hypnotic therapy every 3 months.
Comparator HMO 2, with approximately 220,000
members, placed no edit and served as the control. The
study time frame was January–December 2000. Phar-
macy claims data were used to evaluate the effect of the
edit by identifying the number of prescriptions ﬁlled, the
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total plan cost for these agents and the average cost per
prescription for both HMO 1 and HMO 2. In addition,
trend analysis was performed to ascertain if a shift to the
unedited benzodiazepine hypnotics occurred due to the
edit placed by HMO 1. RESULTS: The total number of
prescriptions ﬁlled for zolpidem and zaleplon was 13,783
for HMO 1 vs 15,313 for HMO 2 with total plan costs
of $512,512 for HMO 1 vs $680,689 for HMO 2. The
average cost per prescription for zolpidem was $38.05
and for zaleplon was $26.56 for HMO 1 vs. $44.32 and
$45.63 respectively for HMO 2. Trend analysis demon-
strated no shift in utilization to benzodiazepine hypnotics
for HMO 1. Cost avoidance was calculated by taking 
the difference in average prescription cost, by agent, for
HMO 2 and subtracting the applicable average prescrip-
tion cost for HMO 1. This cost avoided was then multi-
plied by the number of prescriptions ﬁlled, by agent, for
HMO 1, to achieve the total cost avoided. The total cost
avoidance achieved for HMO 1 was nearly $100,000.
CONCLUSION: Appropriate use edits administered by
the Pharmacy Beneﬁts Manager can achieve signiﬁcant
cost avoidance outcomes for HMO clients.
MENTAL HEALTH—Quality of Life/Preference
Based Outcomes
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OBJECTIVE: To concurrently validate three health-
related quality of life (HRQOL) measures in patients with
schizophrenia in Singapore. METHODS: A consecutive
sample of outpatients with schizophrenia seen at a psy-
chiatric hospital completed English or Chinese versions
of the Schizophrenia Quality of Life Scale (SQLS) and the
Short Form 36 Health Survey (SF-36) twice during 2 dif-
ferent visits. At baseline, patients also completed the
Health Utilities Index Mark 3 (HUI3) and were assessed
for psychotic symptoms using a standard checklist. Con-
struct validity was assessed using factor analysis, item-
scale correlation matrix and by examining hypothesized
correlations; reliability using Cronbach’s alpha and 
intraclass correlation coefﬁcients (ICC); and responsive-
ness using Cohen’s effect size measure (d) and paired t-
tests. RESULTS: Baseline and follow-up surveys were
completed by 202 (English-speaking = 140) and 117 sub-
jects respectively (median interval: 25 days). Item-scale
correlation matrix and factor analysis results supported
construct validity of the SQLS. Correlations between the
three measures and psychotic symptoms were generally
as hypothesized (Spearman’s rho: 0.20–0.61, p < 0.01 for
all). Cronbach’s alpha ranged from 0.59 to 0.93 for SQLS
and 0.57 to 0.82 for SF-36 scales. ICCs ranged from 0.46
to 0.82 for SQLS and 0.32 to 0.59 for SF-36 scales. SQLS
psychosocial and SF-36 role-physical, general health,
vitality, social functioning and role-emotional scale scores
improved with improvements in self-reported global
health; SQLS symptoms/side effects and SF-36 social
functioning scale scores worsened with worsening self-
reported global health (effect size: 0.3–0.4, paired t-tests:
p < 0.05 for all). English and Chinese versions of the
SQLS showed similar degrees of construct validity, relia-
bility and responsiveness. CONCLUSIONS: The SQLS,
SF-36 and HUI3 appear to be valid, reliable and respon-
sive (for the SQLS & SF-36) HRQOL measures in out-
patients with schizophrenia in Singapore. Singaporean
English and Chinese versions of SQLS appear to be psy-
chometrically equivalent.
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OBJECTIVE: To assess how subjective tolerability to
medication compares in patients taking ziprasidone or
haloperidol for acute schizophrenia. METHODS: A 6-
week parallel-group, open-label study randomly assigned
555 patients with acute schizophrenia to sequential
IM/oral ziprasidone (<40mg IM for < 3 days, 40 to 
80mg oral thereafter) or haloperidol (<10mg IM for < 3
days, 5 to 20mg oral thereafter). A 10-question Drug
Attitude Inventory (DAI) was administered at random-
ization (baseline), Days 1–3, Week 1, and Week 6 or end-
point. Primary outcome was DAI total score by visit and
change from baseline. Additional outcomes were DAI
subjective positive score, subjective total score, and atti-
tudes/values score. Factor loading and standardized dis-
criminant coefﬁcients were applied. Inferential analyses
were based on main effects ANCOVA. RESULTS:
Patients in the ziprasidone group exhibited statistically
signiﬁcant improvement in subjective tolerability over
patients in the haloperidol group, as measured by DAI
scores: total score after Week 1 (P < 0.01), subjective 
positive score after Week 1 (P < 0.01), and subjective 
total scores after IM therapy (P < 0.05) and Week 1 (P <
0.001). CONCLUSIONS: Patients with acute schizo-
phrenia manifest better feelings about using ziprasidone
than haloperidol, especially at treatment outset (IM phase
through transition to oral dosing). These ﬁndings have
implications for better patient management during acute
exacerbations, for smooth transition from IM to oral
treatment, and for improved compliance with long-term
ziprasidone therapy.
